Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Main|Search|PHGKB
Search PHGKB:

Last Posted: Apr 09, 2024
spot light Highlights

Clinical implementation of preemptive pharmacogenomics in psychiatry.
Maria Skokou et al. EBioMedicine 2024 2 105009

From the abstract: "We report our findings from a multicenter, large-scale, prospective study of pre-emptive genome-guided treatment named as PREemptive Pharmacogenomic testing for preventing Adverse drug REactions (PREPARE) in a large cohort of psychiatric patients (n = 1076) suffering from schizophrenia, major depressive disorder and bipolar disorder.We show that patients with an actionable phenotype belonging to the PGx-guided arm (n = 25) present with 34.1% less adverse drug reactions compared to patients belonging to the control arm (n = 36), 41.2% less hospitalisations (n = 110 in the PGx-guided arm versus n = 187 in the control arm) and 40.5% less re-admissions (n = 19 in the PGx-guided arm versus n = 32 in the control arm). "

Medical AI falters when assessing patients it hasn’t seen
M Nadaf, Nature, January 11, 2024

From the article: "Computer algorithms that are designed to help doctors treat people with schizophrenia do not adapt well to fresh, unseen data, a study has found. Such tools — which use artificial intelligence (AI) to spot patterns in large data sets and predict how individuals will respond to a particular treatment — are central to precision medicine, in which health-care professionals try to tailor treatment to each person. "

Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia: A Randomized Clinical Trial.
Zhewei Kang et al. JAMA Netw Open 2023 10 (10) e2335518

From the abstract: "What is the therapeutic efficacy of multigenic pharmacogenomics–guided treatment in patients with schizophrenia? In this randomized clinical trial that included 210 Chinese Han men, patients treated with multigenetic pharmacogenomics–guided treatment had a greater symptom improvement than those treated with treatment as usual after a 6-week treatment, measured as the mean difference in percentage change of Positive and Negative Syndrome Scale score. Meaning Multigenetic pharmacogenomic testing can be an effective tool to guide the treatment of schizophrenia. "

Schizophrenia Linked With Genetic Changes That Are Not Inherited.
Emily Harris et al. JAMA 2023 7

Previous research has linked heritable genetic changes with schizophrenia. But genetic changes that occur in utero and are not inherited might also be associated with developing schizophrenia later, according to new data from more than 24?000 people with and without the condition. The study found that deletions in 2 genes were more common in people with schizophrenia. The first gene, NRXN1, encodes a protein involved in brain signaling. The second, ABCB11, is enriched in dopaminergic neurons in a subset of people with treatment-resistant schizophrenia who were taking clozapine,

Search Result Summary


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP